Advertisement
Mayo Clinic Proceedings Home

Prevention, Diagnosis, and Treatment of Cervical Cancer

      This article reviews the current data on human papillomavirus as the cause of most cervical cancer cases, data on the recently approved human papillomavirus vaccines, and updated information concerning the Bethesda System for interpretation of Papanicolaou test results. Current recommendations for surgical treatment, concurrent chemotherapy, and radiation therapy and recent advances in systemic therapy for advanced or metastatic cervical cancer are reviewed.
      CIN (cervical intraepithelial neoplasia), FIGO (Fédération Internationale de Gynécologie et d'Obstétrique), GOG (Gynecologic Oncology Group), HDR (high-dose rate), HPV (human papillomavirus), HR (hazard ratio), LDR (low-dose rate), Pap (Papanicolaou)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Jemal A
        • Siegel R
        • Ward E
        • et al.
        Cancer statistics, 2006.
        CA Cancer J Clin. 2006; 56: 106-130
        • Parkin DM
        • Bray F
        • Ferlay J
        • Pisani P
        Global cancer statistics, 2002.
        CA Cancer J Clin. 2005; 55: 74-108
        • Kulasingam SL
        • Hughes JP
        • Kiviat NB
        • et al.
        Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
        JAMA. 2002; 288: 1749-1757
        • Munoz N
        • Bosch FX
        • de Sanjose S
        • International Agency for Research on Cancer Multicenter Cervical Cancer Study Group
        • et al.
        Epidemiologic classification of human papillomavirus types associated with cervical cancer.
        N Engl J Med. 2003; 348: 518-527
        • Clifford GM
        • Smith JS
        • Plummer M
        • Munoz N
        • Franceschi S
        Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis.
        Br J Cancer. 2003; 88: 63-73
        • Manhart LE
        • Koutsky LA
        Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? a meta-analysis.
        Sex Transm Dis. 2002; 29: 725-735
        • Winer RL
        • Hughes JP
        • Feng Q
        • et al.
        Condom use and the risk of genital human papillomavirus infection in young women.
        N Engl J Med. 2006; 354: 2645-2654
        • Walboomers JM
        • Jacobs MV
        • Manos MM
        • et al.
        Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.
        J Pathol. 1999; 189: 12-19
        • Bosch FX
        • Manos MM
        • Munoz N
        • International Biological Study on Cervical Cancer (IBSCC) Study Group
        • et al.
        Prevalence of human papillomavirus in cervical cancer: a worldwide perspective.
        J Natl Cancer Inst. 1995; 87: 796-802
        • McGlennen RC
        Human papillomavirus oncogenesis.
        Clin Lab Med. 2000; 20: 383-406
        • Stanley MA
        Human papillomavirus and cervical carcinogenesis.
        Best Pract Res Clin Obstet Gynaecol. 2001; 15: 663-676
        • Liu JS
        • Kuo SR
        • Broker TR
        • Chow LT
        The functions of human papillomavirus type 11 E1, E2, and E2C proteins in cell-free DNA replication.
        J Biol Chem. 1995; 270: 27283-27291
        • Van Tine BA
        • Dao LD
        • Wu S
        • et al.
        Human papillomavirus (HPV) origin-binding protein associates with mitotic spindles to enable viral DNA partitioning.
        Proc Natl Acad Sci U S A. 2004 Mar 23; 101 (Epub 2004 Mar 12.): 4030-4035
        • Kirnbauer R
        • Booy F
        • Cheng N
        • Lowy DR
        • Schiller JT
        Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.
        Proc Natl Acad Sci U S A. 1992; 89: 12180-12184
        • Koutsky LA
        • Ault KA
        • Wheeler CM
        • Proof of Principle Study Investigators
        • et al.
        A controlled trial of human papillomavirus type 16 vaccine.
        N Engl J Med. 2002; 347: 1645-1651
        • Harper DM
        • Franco EL
        • Wheeler CM
        • HPV Vaccine Study Group
        • et al.
        Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.
        Lancet. 2006; 367: 1247-1255
        • Villa LL
        • Costa RL
        • Petta CA
        • et al.
        Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.
        Lancet Oncol. 2005; 6: 271-278
        • Lowy DR
        • Schiller JT
        Prophylactic human papillomavirus vaccines.
        J Clin Invest. 2006; 116: 1167-1173
        • Gustafsson L
        • Ponten J
        • Zack M
        • Adami HO
        International incidence rates of invasive cervical cancer after introduction of cytological screening.
        Cancer Causes Control. 1997; 8: 755-763
        • Baer A
        • Kiviat NB
        • Kulasingam S
        • Mao C
        • Kuypers J
        • Koutsky LA
        Liquid-based Papanicolaou smears without a transformation zone component: should clinicians worry?.
        Obstet Gynecol. 2002; 99: 1053-1059
        • Bidus MA
        • Maxwell GL
        • Kulasingam S
        • et al.
        Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening.
        Obstet Gynecol. 2006; 107: 997-1005
        • Bundrick JB
        • Cook DA
        • Gostout BS
        Screening for cervical cancer and initial treatment of patients with abnormal results from Papanicolaou testing.
        Mayo Clin Proc. 2005; 80: 1063-1068
        • Solomon D
        • Davey D
        • Kurman R
        • Forum Group Members, Bethesda 2001 Workshop
        • et al.
        The 2001 Bethesda System: terminology for reporting results of cervical cytology.
        JAMA. 2002; 287: 2114-2119
        • Ho GY
        • Bierman R
        • Beardsley L
        • Chang CJ
        • Burk RD
        Natural history of cervicovaginal papillomavirus infection in young women.
        N Engl J Med. 1998; 338: 423-428
        • Woodman CB
        • Collins S
        • Winter H
        • et al.
        Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study.
        Lancet. 2001; 357: 1831-1836
        • Holowaty P
        • Miller AB
        • Rohan T
        • To T
        Natural history of dysplasia of the uterine cervix.
        J Natl Cancer Inst. 1999; 91: 252-258
        • Garland SM
        Human papillomavirus update with a particular focus on cervical disease.
        Pathology. 2002; 34: 213-224
        • Spriggs AI
        • Boddington MM
        Progression and regression of cervical lesions: review of smears from women followed without initial biopsy or treatment.
        J Clin Pathol. 1980; 33: 517-522
        • Kosary CL
        FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina.
        Semin Surg Oncol. 1994; 10: 31-46
        • Schlecht NF
        • Burk RD
        • Palefsky JM
        • et al.
        Variants of human papillomaviruses 16 and 18 and their natural history in human immunodeficiency virus-positive women.
        J Gen Virol. 2005; 86: 2709-2720
        • Holcomb K
        • Maiman M
        • Dimaio T
        • Gates J
        Rapid progression to invasive cervix cancer in a woman infected with the human immunodeficiency virus.
        Obstet Gynecol. 1998; 91: 848-850
        • Cooksley CD
        • Hwang LY
        • Waller DK
        • Ford CE
        HIV-related malignancies: community-based study using linkage of cancer registry and HIV registry data.
        Int J STD AIDS. 1999; 10: 795-802
        • Plummer M
        • Herrero R
        • Franceschi S
        • IARC Multi-centre Cervical Cancer Study Group
        • et al.
        Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study.
        Cancer Causes Control. 2003; 14: 805-814
      1. International Federation of Gynecology and Obstetrics FIGO staging of gynecologic cancers: cervical and vulva.
        Int J Gynecol Cancer. 1995; 5: 319-324
        • American Joint Committee on Cancer
        Cervix uteri.
        in: Greene FL Page DL Fleming ID AJCC Cancer Staging Handbook. 6th ed. Springer, New York, NY2002: 259-265
        • Papanikolaou A
        • Kalogiannidis I
        • Misailidou D
        • et al.
        Results on the treatment of uterine cervix cancer: ten years experience.
        Eur J Gynaecol Oncol. 2006; 27: 607-610
        • Sedlis A
        • Bundy BN
        • Rotman MZ
        • Lentz SS
        • Muderspach LI
        • Zaino RJ
        A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group study.
        Gynecol Oncol. 1999; 73: 177-183
        • Rotman M
        • Sedlis A
        • Piedmonte MR
        • et al.
        A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study.
        Int J Radiat Oncol Biol Phys. 2006 May 1; 65 (Epub 2006 Jan 19.): 169-176
        • Kolstad P
        Follow-up study of 232 patients with stage Ia1 and 411 patients with stage Ia2 squamous cell carcinoma of the cervix (microinvasive carcinoma).
        Gynecol Oncol. 1989; 33: 265-272
        • Creasman WT
        • Zaino RJ
        • Major FJ
        • DiSaia PJ
        • Hatch KD
        • Homesley HD
        Early invasive carcinoma of the cervix (3 to 5 mm invasion): risk factors and prognosis: a Gynecologic Oncology Group study.
        Am J Obstet Gynecol. 1998; 178: 62-65
        • Plante M
        • Renaud MC
        • Hoskins IA
        • Roy M
        Vaginal radical trachelectomy: a valuable fertility-preserving option in the management of early-stage cervical cancer: a series of 50 pregnancies and review of the literature.
        Gynecol Oncol. 2005; 98: 3-10
        • Peters III, WA
        • Liu PY
        • Barrett II, RJ
        • et al.
        Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix.
        J Clin Oncol. 2000; 18: 1606-1613
        • National Institutes of Health
        Cervical cancer.
        NIH Consens Statement. 1996; 14: 1-38
        • Green JA
        • Kirwan JM
        • Tierney JF
        • et al.
        Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis.
        Lancet. 2001; 358: 781-786
        • Lanciano RM
        • Martz K
        • Coia LR
        • Hanks GE
        Tumor and treatment factors improving outcome in stage III-B cervix cancer.
        Int J Radiat Oncol Biol Phys. 1991; 20: 95-100
        • Logsdon MD
        • Eifel PJ
        FIGO IIIB squamous cell carcinoma of the cervix: an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy.
        Int J Radiat Oncol Biol Phys. 1999; 43: 763-775
        • Nag S
        • Chao C
        • Erickson B
        • American Brachytherapy Society
        • et al.
        The American Brachytherapy Society recommendations for low-dose-rate brachytherapy for carcinoma of the cervix.
        Int J Radiat Oncol Biol Phys. 2002; 52: 33-48
        • Withers HR
        • Taylor JM
        • Maciejewski B
        The hazard of accelerated tumor clonogen repopulation during radiotherapy.
        Acta Oncol. 1988; 27: 131-146
        • Fyles A
        • Keane TJ
        • Barton M
        • Simm J
        The effect of treatment duration in the local control of cervix cancer.
        Radiother Oncol. 1992; 25: 273-279
        • Mundt AJ
        • Lujan AE
        • Rotmensch J
        • et al.
        Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies.
        Int J Radiat Oncol Biol Phys. 2002; 52: 1330-1337
        • Gaffney DK
        • Du Bois A
        • Narayan K
        • et al.
        Practice patterns of radiotherapy in cervical cancer among member groups of the Gynecologic Cancer Intergroup (GCIG).
        Int J Radiat Oncol Biol Phys. 2007 Jun 1; 68 (Epub 2007 Mar 2.): 485-490
        • Erickson B
        • Eifel P
        • Moughan J
        • Rownd J
        • Iarocci T
        • Owen J
        Patterns of brachytherapy practice for patients with carcinoma of the cervix (1996-1999): a patterns of care study.
        Int J Radiat Oncol Biol Phys. 2005 Nov 15; 63 (Epub 2005 Aug 15.): 1083-1092
        • Neoadjuvant Chemotherapy for Cervical Cancer Meta-Analysis Collaboration
        Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials.
        Eur J Cancer. 2003; 39: 2470-2486
        • Thigpen T
        • Shingleton H
        • Homesley H
        • Lagasse L
        • Blessing J
        Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
        Cancer. 1981; 48: 899-903
        • Bonomi P
        • Blessing JA
        • Stehman FB
        • DiSaia PJ
        • Walton L
        • Major FJ
        Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study.
        J Clin Oncol. 1985; 3: 1079-1085
        • Omura GA
        • Blessing JA
        • Vaccarello L
        • et al.
        Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study.
        J Clin Oncol. 1997; 15: 165-171
        • Moore DH
        • Blessing JA
        • McQuellon RP
        • et al.
        Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
        J Clin Oncol. 2004; 22: 3113-3119
        • Long III, HJ
        • Bundy BN
        • Grendys Jr, EC
        • et al.
        Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study.
        J Clin Oncol. 2005 Jul 20; 23 (Epub 2005 May 23.): 4626-4633